Gefitinib is an anti-cancer medication used to treat non-small cell lung cancer (NSCLC). It works by inhibiting the action of epidermal growth factor receptor (EGFR), which is involved in cancer cell growth. Gefitinib is effective for patients with specific mutations and may cause side effects such as diarrhea and rash. In summary, Gefitinib is essential for targeted lung cancer therapy.
Gefitinib selectively inhibits EGFR tyrosine kinase, blocking downstream signaling pathways involved in cancer cell proliferation and survival.





